HIK vs. HCM, INDV, AMYT, APH, AGY, ANCR, VLG, DNL, EAH, and STX
Should you be buying Hikma Pharmaceuticals stock or one of its competitors? The main competitors of Hikma Pharmaceuticals include HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Alliance Pharma (APH), Allergy Therapeutics (AGY), Animalcare Group (ANCR), Venture Life Group (VLG), Diurnal Group (DNL), ECO Animal Health Group (EAH), and Shield Therapeutics (STX). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Hikma Pharmaceuticals vs.
Hikma Pharmaceuticals (LON:HIK) and HUTCHMED (LON:HCM) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, community ranking, dividends, profitability and analyst recommendations.
In the previous week, Hikma Pharmaceuticals had 3 more articles in the media than HUTCHMED. MarketBeat recorded 4 mentions for Hikma Pharmaceuticals and 1 mentions for HUTCHMED. Hikma Pharmaceuticals' average media sentiment score of 0.58 beat HUTCHMED's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.
Hikma Pharmaceuticals presently has a consensus target price of GBX 2,436.67, suggesting a potential upside of 22.75%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.
42.1% of Hikma Pharmaceuticals shares are held by institutional investors. Comparatively, 36.5% of HUTCHMED shares are held by institutional investors. 30.5% of Hikma Pharmaceuticals shares are held by insiders. Comparatively, 39.0% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Hikma Pharmaceuticals received 607 more outperform votes than HUTCHMED when rated by MarketBeat users. However, 78.40% of users gave HUTCHMED an outperform vote while only 70.62% of users gave Hikma Pharmaceuticals an outperform vote.
Hikma Pharmaceuticals has a net margin of 9.45% compared to HUTCHMED's net margin of -6.87%. Hikma Pharmaceuticals' return on equity of 12.71% beat HUTCHMED's return on equity.
Hikma Pharmaceuticals has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.
Summary
Hikma Pharmaceuticals beats HUTCHMED on 14 of the 18 factors compared between the two stocks.
Get Hikma Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hikma Pharmaceuticals Competitors List
Related Companies and Tools
This page (LON:HIK) was last updated on 5/1/2025 by MarketBeat.com Staff
